Essential (hemorrhagic) thrombocythemia. D47.3 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2019 edition of ICD-10-CM D47.3 became effective on October 1, 2018.
Search the full ICD-10 catalog by:
The new codes are for describing the infusion of tixagevimab and cilgavimab monoclonal antibody (code XW023X7), and the infusion of other new technology monoclonal antibody (code XW023Y7).
The ICD-10-CM is a catalog of diagnosis codes used by medical professionals for medical coding and reporting in health care settings. The Centers for Medicare and Medicaid Services (CMS) maintain the catalog in the U.S. releasing yearly updates.
839.
Thrombocythemia and thrombocytosis are conditions that occur when your blood has a higher-than-normal platelet count. Platelets are tiny blood cells. They are made in your bone marrow along with other kinds of blood cells.
With primary thrombocythemia, a high platelet count may occur alone or with other blood cell disorders. This condition isn't common. When another disease or condition causes a high platelet count, the term "thrombocytosis" is preferred. This condition often is called secondary or reactive thrombocytosis.
reactive thrombocytosis (D75.838)secondary thrombocytosis (D75.838)thrombocythemia NOS (D75.839)thrombocytosis NOS (D75.839)
Essential thrombocythemia (ET) was the most common cause of primary thrombocytosis. Among secondary, non-infectious etiologies, tissue damage was the most common, followed by malignancy and iron-deficiency anemia. The most common infectious causes of thrombocytosis were soft-tissue, pulmonary and GI infections.
The cause of this disorder is unclear but it often appears to be connected to mutations in a variety of genes. Your bone marrow produces too many of the cells that form platelets and these platelets are often abnormal.
Thrombocytosis is an adverse prognostic factor in many types of cancer. These include breast cancer, ovarian and other gynecologic cancers, renal cell carcinoma and lung cancers.
A complete blood count (CBC) measures the levels of red blood cells, white blood cells, and platelets in your blood. For this test, a small amount of blood is drawn from a blood vessel, usually in your arm. If you have thrombocythemia or thrombocytosis, the CBC results will show that your platelet count is high.
A recent increase in the platelet count was associated with risk of colon cancer (OR, 5.52; 95% CI, 5.21-5.86), lung cancer (OR, 4.77; 95% CI, 4.51-5.04), ovarian cancer (OR, 7.23; 95% CI, 6.12-8.53), and stomach cancer (OR, 5.51; 95% CI, 4.82-6.29) (Figure 3 and eTable 7 in the Supplement).
Primary thrombocytosis is a myeloproliferative disease, caused by monoclonal or polyclonal abnormalities of haematopoietic cells or by abnormalities in the biology of Tpo. Secondary thrombocytosis is caused by stimulated megakaryopoiesis because of various haematological or non-haematological disorders.
Essential thrombocythemia is a chronic disease with no cure. If you have a mild form of the disease, you may not need treatment. If you have severe symptoms, you may need medicine that lowers your platelet count, blood thinners or both.
Secondary thrombocytosis is the more common type and is usually identified in routine laboratory results. Among individuals with thrombocytosis, 80% to 90% are known to have secondary thrombocytosis.